Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sana Biotechnology, Inc.SANA · Entity 4870 | EVP & General Counsel | June 13, 2022 | June 15, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sana Biotechnology, Inc.
Report date June 13, 2022 · Filed June 15, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 497,396 |
Ending reported balance
After 2022-06-13 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-05-13 · Grant · Acquired 1,183 · Balance 430,600 F1: The reporting person is voluntarily reporting the acquisition of shares of common stock of Sana Biotechnology, Inc. (the "Issuer") pursuant to the Sana Biotechnology, Inc. 2021 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of November 17, 2021 through May 13, 2022. This transaction is exempt under Rule 16b-3(c). F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 13, 2022. Row 2 · 2022-06-13 · Exercise / conversion · Acquired 66,796 · Balance 497,396 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2030-01-26 | Direct | 51,954 |
Reported balance
After 2022-06-13 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2022-06-13 · Exercise / conversion · Disposed 66,796 · Balance 51,954 F3: 25% of the shares underlying the option vested and became exercisable on February 14, 2021, and the remainder of the shares underlying the option vest at a rate of 1/36th per month thereafter. |
| Common StockSEC Table I · non-derivative | IndirectHeld by The James J. MacDonald and Rena Chng Trust dtd 01/15/10 | 7,812 |
Reported balance
Holding disclosure · report date 2022-06-13 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 7,812 |
| Common StockSEC Table I · non-derivative | IndirectHeld by the KOM Trust | 125,000 |
Reported balance
Holding disclosure · report date 2022-06-13 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 125,000 |
| Common StockSEC Table I · non-derivative | IndirectHeld by the NMM Trust | 125,000 |
Reported balance
Holding disclosure · report date 2022-06-13 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 125,000 |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person is voluntarily reporting the acquisition of shares of common stock of Sana Biotechnology, Inc. (the "Issuer") pursuant to the Sana Biotechnology, Inc. 2021 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of November 17, 2021 through May 13, 2022. This transaction is exempt under Rule 16b-3(c).
F2: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 13, 2022.
F3: 25% of the shares underlying the option vested and became exercisable on February 14, 2021, and the remainder of the shares underlying the option vest at a rate of 1/36th per month thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2022 Filed Jun 15, 2022 22:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionStock Option (Right to Buy) · Derivative | 66,796 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001562180-22-005121 · primarydocument.xml · derivative · entry 6 MacDonald James J. · CIK 0001830054 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,954 Underlying: Common Stock · 66,796 shares Expires 2030-01-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares underlying the option vested and became exercisable on February 14, 2021, and the remainder of the shares underlying the option vest at a rate of 1/36th per month thereafter. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 22:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | Exercise / conversionCommon Stock | 66,796 | $1.48 | $98,858.08 |
DisclosureSEC source: 0001562180-22-005121 · primarydocument.xml · nonDerivative · entry 2 MacDonald James J. · CIK 0001830054 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 497,396 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 13, 2022 Filed Jun 15, 2022 22:16 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantCommon Stock | 1,183 | $4.28 | $5,067.97 |
DisclosureSEC source: 0001562180-22-005121 · primarydocument.xml · nonDerivative · entry 1 MacDonald James J. · CIK 0001830054 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,600 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock of Sana Biotechnology, Inc. (the "Issuer") pursuant to the Sana Biotechnology, Inc. 2021 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of November 17, 2021 through May 13, 2022. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on May 13, 2022. Read SEC document |
| March 03, 2022 Filed Mar 8, 2022 14:04 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantStock Options (Right to Buy) · Derivative | 225,000 | $0.00 Strike: $5.70 | $0.00 |
DisclosureSEC source: 0001562180-22-002426 · primarydocument.xml · derivative · entry 1 MacDonald James J. · CIK 0001830054 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 225,000 Underlying: Common Stock · 225,000 shares Expires 2032-03-02 F1 · derivative.exercise_date: The option vests and becomes exercisable as to 25% of the underlying shares on March 3, 2023 and in 36 equal monthly installments thereafter. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 22:01 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | SaleCommon Stock | 333 | $6.28 | $2,091.24 |
DisclosureSEC source: 0001562180-22-001784 · primarydocument.xml · nonDerivative · entry 2 MacDonald James J. · CIK 0001830054 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,417 F3 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 4, 2021. Read SEC document |
| November 15, 2021 Filed Feb 23, 2022 22:01 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | GrantCommon Stock | 1,000 | $18.23 | $18,232.50 |
DisclosureSEC source: 0001562180-22-001784 · primarydocument.xml · nonDerivative · entry 1 MacDonald James J. · CIK 0001830054 · EVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 429,750 F1 · kind: The reporting person is voluntarily reporting the acquisition of shares of common stock of Sana Biotechnology, Inc. (the "Issuer") pursuant to the Sana Biotechnology, Inc. 2021 Employee Stock Purchase Plan ("ESPP") for the ESPP purchase period of February 3, 2021 through November 15, 2021. This transaction is exempt under Rule 16b-3(c). F2 · price: In accordance with the ESPP, these shares were purchased based on 85% of the closing price of the Issuer's common stock on November 15, 2021. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | ConversionSeries B Convertible Preferred Stock · Derivative | 7,812 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005728 · doc4.xml · derivative · entry 6 MacDonald James J. · CIK 0001830054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The James J. MacDonald and Rena Chng Trust dtd 01/15/10 Disclosed balance after: 0 Underlying: Common Stock · 7,812 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | ConversionSeries A-1 Convertible Preferred Stock · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-005728 · doc4.xml · derivative · entry 5 MacDonald James J. · CIK 0001830054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 93,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F1 · derivative.exercise_date: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. F2 · derivative.expiration_date: The expiration date is not relevant to the conversion of these securities. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | ConversionCommon Stock | 7,812 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-005728 · doc4.xml · nonDerivative · entry 2 MacDonald James J. · CIK 0001830054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Indirect · Held by The James J. MacDonald and Rena Chng Trust dtd 01/15/10 Disclosed balance after: 7,812 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. Read SEC document |
| February 08, 2021 Filed Feb 10, 2021 23:40 UTC | Sana Biotechnology, Inc. SANA · Entity 4870 | ConversionCommon Stock | 93,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-005728 · doc4.xml · nonDerivative · entry 1 MacDonald James J. · CIK 0001830054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 428,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The shares of Issuer's Preferred Stock automatically convert into shares of Issuer's Common Stock, for no additional consideration, on a 1-for-1 basis immediately prior to the consummation of Issuer's initial public offering. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.